<DOC>
	<DOC>NCT02068690</DOC>
	<brief_summary>To investigate safety, tolerability, and pharmacokinetics of BI 425809 following single rising doses of BI 425809 in healthy male volunteers; To explore dose proportionality of BI 425809 as oral drinking solution; To investigate relative bioavailability of BI 425809 oral drinking solution fasted compared to BI 425809 tablet fasted and tablet fed</brief_summary>
	<brief_title>Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809</brief_title>
	<detailed_description />
	<criteria>Inclusion criteria: Healthy male subjects Age 18 to 45 years (incl.) Body mass index (BMI) 18.5 to 29.9 kg/m2 (incl.) Subject must be able to understand and comply with study requirements Exclusion criteria: Any finding in the medical examination (including blood pressure (BP), pulse rate (PR) or electrocardiogram (ECG)) deviating from normal and judged clinically relevant by the investigator Repeated measurement of systolic blood pressure &lt;90 or &gt;140 mmHg, or diastolic blood pressure &lt;50 or &gt;90 mmHg, or pulse rate &lt;50 or &gt;90 Any laboratory value outside the reference range that the investigator considers to be of clinical relevance Any evidence of a concomitant disease judged clinically relevant by the investigator Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Surgery of the gastrointestinal tract that could interfere with kinetics of the study drug(s) Diseases of the central nervous system (such as epilepsy), other neurological disorders or psychiatric disorders</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>